Investigational drug · Phase 2
SHR-7787
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Malignant Solid Tumors, Limited-stage Small-cell Lung Cancer, Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "SHR-7787"
First trial start
2024
Oct 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-7787", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Solid Tumors
- Limited-stage Small-cell Lung Cancer
- Advanced Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-7787" as an intervention, largest first.
Hansoh BioMedical R&D CompanyIndustry
NCT06936735 · 502 participants (planned) · Start May 29, 2025 · Primary completion Aug 31, 2028
Drug: HS-20108 Monotherapy · For: Advanced Solid Tumor
Sites: Shanghai, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT07268040 · 400 participants (planned) · Start Dec 23, 2025 · Primary completion Dec 2028
Drug: SHR-7787 Injection; SHR-1316 Injection and 5 more · For: Malignant Solid Tumors
Sites: Wuhan, China; Shanghai, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06605222 · 201 participants (planned) · Start Oct 4, 2024 · Primary completion Dec 2026
Drug: SHR-7787 injection · For: Advanced Solid Tumors
Sites: Shanghai, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT07798947 · 120 participants (planned) · Start Oct 7, 2026 · Primary completion Dec 2028
Drug: SHR-7787 Injection; SHR-1316 · For: Limited-stage Small-cell Lung Cancer
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Malignant Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- SHR-4849Phase 22 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors
- SHR-1681Phase 21 trial
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors
- SHR-4298Phase 21 trial
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors
- TAK-505Phase 21 trial
Takeda · Malignant Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.